Langan, J, Shajahan, P.
Antipsychotic polypharmacy: review of mechanisms, mortality and management. Psychiatrist
2009; 34: 58–62.
Tungaraza, TE, Gupta, S, Jones, J, Poole, R, Slegg, G.
Polypharmacy and high-dose antipsychotic regimes in the community. Psychiatrist
2009; 34: 44–6.
Paton, C, Barnes, TRE, Cavanagh, MR, Taylor, D, Lelliott, P, the POMH-UK project team. High-dose and combination antipsychotic prescribing in acute adult wards in the UK: the challenges posed by p.r.n. prescribing. Br J Psychiatry
2008; 192: 435–9.
Beasley, CM Jr, Sanger, T, Satterlee, W, Tollefson, G, Tran, P, Hamilton, S, et al. Olanzapine versus placebo: results of a double-blind, fixed-dose olanzapine trial. Psychopharmacology
1996; 124: 159–67.
Borison, RL, Arvanitis, LA, Miller, BG. ICI 204,636, an atypical antipsychotic: efficacy and safety in a multicenter, placebo-controlled trial in patients with schizophrenia. U.S. SEROQUEL Study Group. J Clin Psychopharmacol
1996; 16: 158–69.
Taylor, DM, Young, C, Paton, C.
Prior antipsychotic prescribing in patients currently receiving clozapine: a case note review. J Clin Psychiatry
2003; 64: 30–4.
Carpenter, WT Jr, Zito, JM, Vitrai, J, Volavka, J.
Hypothesis testing: is clozapine's superior efficacy dependent on moderate D2 receptor occupancy?
1998; 43: 79–83.
Pilowsky, LS, Mulligan, RS, Acton, PD, Ell, PJ, Costa, DC, Kerwin, RW. Limbic selectivity of clozapine. Lancet
1997; 350: 490–1.
Barbui, C, Signoretti, A, Mule, S, Boso, M, Cipriani, A.
Does the addition of a second antipsychotic drug improve clozapine treatment?
2009; 35: 458–68.
Taylor, DM, Smith, L.
Augmentation of clozapine with a second antipsychotic – a meta-analysis of randomized, placebo-controlled studies. Acta Psychiatr Scand
2009; 119: 419–25.
Cipriani, A, Boso, M, Barbui, C.
Clozapine combined with different antipsychotic drugs for treatment resistant schizophrenia. Cochrane Database Syst Rev
Correll, CU, Rummel-Kluge, C, Corves, C, Kane, JM, Leucht, S.
Antipsychotic combinations vs monotherapy in schizophrenia: a meta-analysis of randomized controlled trials. Schizophr Bull
2009; 35: 443–57.
Kreyenbuhl, J, Marcus, SC, West, JC, Wilk, J, Olfson, M.
Adding or switching antipsychotic medications in treatment-refractory schizophrenia. Psychiatr Serv
2007; 58: 983–90.
Taylor, D, Holmes, R, Hilton, T, Paton, C.
Evaluating and improving the quality of risperidone prescribing. Psychiatr Bull
1997; 21: 680–3.
Taylor, D, Mace, S, Mir, S, Kerwin, R.
A prescription survey of the use of atypical antipsychotics for hospital inpatients in the United Kingdom. Int J Psychiatry Clin Pract
2000; 4: 41–6.
Waddington, JL, Youssef, HA, Kinsella, A.
Mortality in schizophrenia. Antipsychotic polypharmacy and absence of adjunctive anticholinergics over the course of a 10-year prospective study. Br J Psychiatry
1998; 173: 325–9.
Centorrino, F, Goren, JL, Hennen, J, Salvatore, P, Kelleher, JP, Baldessarini, RJ. Multiple versus single antipsychotic agents for hospitalized psychiatric patients: case-control study of risks versus benefits. Am J Psychiatry
2004; 161: 700–6.
Elie, D, Poirier, M, Chianetta, J, Durand, M, Gregoire, C, Grignon, S.
Cognitive effects of antipsychotic dosage and polypharmacy: a study with the BACS in patients with schizophrenia and schizoaffective disorder. J Psychopharmacol
2009; Epub ahead of print, doi: 10.1177/0269881108100777.
Taylor, D, Young, C, Esop, R, Paton, C, Walwyn, R.
Testing for diabetes in hospitalised patients prescribed antipsychotic drugs. Br J Psychiatry
2004; 185: 152–6.
Paton, C, Esop, R, Young, C, Taylor, D.
Obesity, dyslipidaemias and smoking in an inpatient population treated with antipsychotic drugs. Acta Psychiatr Scand
2004; 110: 299–305.
Taylor, D, Young, C, Mohamed, R, Paton, C, Walwyn, R.
Undiagnosed impaired fasting glucose and diabetes mellitus amongst inpatients receiving antipsychotic drugs. J Psychopharmacol
2005; 19: 182–6.
Correll, CU, Frederickson, AM, Kane, JM, Manu, P.
Does antipsychotic polypharmacy increase the risk for metabolic syndrome?
2007; 89: 91–100.
Connolly, A, Taylor, D.
Ethnicity and quality of antipsychotic prescribing among in-patients in south London. Br J Psychiatry
2008; 193: 161–2.
Ezewuzie, N, Taylor, D.
Establishing a dose-response relationship for oral risperidone in relapsed schizophrenia. J Psychopharmacol
2006; 20: 86–90.
Mace, S, Taylor, D.
Aripiprazole: dose-response relationship in schizophrenia and schizoaffective disorder. CNS Drugs
2008; 23: 773–80.
Van Putten, T, Marder, SR, Mintz, J, Poland, RE. Haloperidol plasma levels and clinical response: a therapeutic window relationship. Am J Psychiatry
1992; 149: 500–5.
Sparshatt, A, Jones, S, Taylor, D.
Quetiapine: dose-response relationship in schizophrenia. CNS Drugs
2008; 22: 49–68.
Establishing a dose-response relationship for haloperidol decanoate. Psychiatr Bull
2005; 29: 104–7.
Kinon, BJ, Volavka, J, Stauffer, V, Edwards, SE, Liu-Seifert, H, Chen, L, et al. Standard and higher dose of olanzapine in patients with schizophrenia or schizoaffective disorder: a randomized, double-blind, fixed-dose study. J Clin Psychopharmacol
2008; 28: 392–400.
Agid, O, Mamo, D, Ginovart, N, Vitcu, I, Wilson, AA, Zipursky, RB, et al. Striatal vs extrastriatal dopamine D2 receptors in antipsychotic response. A double-blind PET study in schizophrenia. Neuropsychopharmacology
2006; 32: 1209–15.
Taylor, D, Paton, C, Kerwin, R.
The Maudsley Prescribing Guidelines (9th edn). Informa Healthcare, 2007.
Fleischhacker, WW, Heikkinen, T, Olie, JP, Landsberg, W, Dewaele, P, McQuade, RD, et al. Weight change on aripiprazole-clozapine combination in schizophrenic patients with weight gain and suboptimal response on clozapine: 16-week double-blind study. Eur Psychiatry
2008; 2 (suppl 23): s114–5.
Shim, JC, Shin, JG, Kelly, DL, Jung, DU, Seo, YS, Liu, KH, et al. Adjunctive treatment with a dopamine partial agonist, aripiprazole, for antipsychotic-induced hyperprolactinemia: a placebo-controlled trial. Am J Psychiatry
2007; 164: 1404–10.
Burris, KD, Molski, TF, Xu, C, Ryan, E, Tottori, K, Kikuchi, T, et al. Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J Pharmacol Exp Ther
2002; 302: 381–9.
Antipsychotic prescribing – time to review practice. Psychiatr Bull
2002; 26: 401–2.
National Institute for Health and Clinical Excellence. Schizophrenia: Core Interventions in the Treatment and Management of Schizophrenia in Primary and Secondary Care (Update). NICE, 2009.